Topics:

All Content

Although e-cigarettes are being put forward as a safer alternative that delivers nicotine without carcinogens and assists smokers to quit, I remained concerned that evidence suggests the products are marketed for purchase and use by children. How else can one explain brands featuring flavors like Gooey Butter Cake, Snicker Doodle, Extra Sweet Cotton Candy, Bananalicious, and—the most outrageous—Gummi Bear.

A combination of amrubicin and cisplatin was inferior to irinotecan and cisplatin in chemotherapy-naïve patients with extensive disease small-cell lung cancer (SCLC) in a phase III trial conducted in Japan.

Dual HER2-targeted treatment with T-DM1 and pertuzumab resulted in positive antitumor activity in patients with HER2-positive, locally advanced or metastatic breast cancer, with an overall response rate of 41%.

Subpopulation of Breast Cancer Patients Most Likely to Respond to Palbociclib

This slide show features some of the highlights from the 105th Annual Meeting of the American Association for Cancer Research (AACR), including a breast cancer trial of .

A 48-year-old woman presents with a soft-tissue nodular lesion in the right forearm. Surgical resection of the lesion is performed. What is your diagnosis?

Patients with localized prostate cancer treated with primary androgen deprivation therapy (ADT) without radiation therapy or surgery derived no survival benefit, according to the results of a large study.

A new pilot study demonstrates the ability of a blood-based test to detect metastatic breast cancer recurrence with high sensitivity and specificity.

This slide show includes highlights from the 2014 Society of Gynecologic Oncology annual meeting, including one study showing bariatric surgery could lower the risk of uterine cancer, and another that found a PARP inhibitor active in BRCA-positive ovarian cancer.

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

Using both clinical and molecular markers, researchers have created a simple prognostic index for patients with cytogenetically normal acute myeloid leukemia (AML).

Pages

Please Wait 20 seconds or click here to close